BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)
Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Nov 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The BATTLE trial is studying how certain types of bacteria in the body might affect the survival of patients with alcoholic hepatitis, a serious liver disease that can be life-threatening. Researchers believe that some bacterial strains could be linked to better chances of survival for these patients. The goal of the trial is to see if targeting these harmful bacteria can help improve outcomes for people suffering from this condition.
To take part in this study, participants must be at least 18 years old and have a history of heavy drinking within the last six months, along with certain health markers indicating how their liver is functioning. People with specific liver cancers, certain viral infections, or other serious health issues that limit their life expectancy will not be eligible. Those who join the trial can expect to undergo tests and monitoring to help researchers understand the relationship between bacteria and liver health. This study is currently recruiting participants of all genders who meet the eligibility criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18
- • Bilirubin \> 50 micromol/L
- • History of large alcoholic consumption in period prior to hospital admission (in the last six months)
- • No bile-duct obstruction (investigated through US, CT og MRI)
- Exclusion Criteria:
- • Hepatocellulary carcinoma
- • Viral hepatitis
- • Autoimmune hepatitis
- • Portal vein thrombosis
- • Pregnancy
- • Expected survival for less than one year caused by other diseases (based on decision from project responsible doctors
About Copenhagen University Hospital, Hvidovre
Copenhagen University Hospital, Hvidovre, is a leading clinical research institution in Denmark, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent academic hospital affiliated with the University of Copenhagen, it integrates cutting-edge research with clinical practice, fostering innovation in various medical fields. The hospital is dedicated to conducting rigorous clinical trials, ensuring adherence to ethical standards and regulatory guidelines, while prioritizing patient safety and welfare. With a multidisciplinary approach and access to diverse patient populations, Copenhagen University Hospital, Hvidovre plays a vital role in translating research findings into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, , Denmark
Patients applied
Trial Officials
frederik cold, MD, PHD
Principal Investigator
Copenhagen University Hospital, Hvidovre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials